Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease

Gastroenterology. 2018 Oct;155(4):1270-1271. doi: 10.1053/j.gastro.2018.06.080. Epub 2018 Sep 15.

Authors

Ciarán P Kelly¹, Mark H Wilcox², Henning Glerup³, Nazimuddin Aboo⁴, Misoo C Ellison⁵, Karen Eves⁵, Mary Beth Dorr⁵

Affiliations

¹ BIDMC and Harvard Medical School, Boston, Massachusetts.
² Leeds Teaching Hospitals and University of Leeds, Leeds, UK.
³ Regionshospitalet, Silkeborg, Denmark.
⁴ Parklands Medical Centre, Overport, Durban, South Africa.
⁵ Merck & Co, Inc, Kenilworth, New Jersey.

PMID: 30227108
DOI: 10.1053/j.gastro.2018.06.080

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Infective Agents / adverse effects
Anti-Infective Agents / therapeutic use*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Neutralizing / adverse effects
Antibodies, Neutralizing / therapeutic use*
Broadly Neutralizing Antibodies
Clinical Trials, Phase III as Topic
Clostridioides difficile / drug effects*
Clostridioides difficile / pathogenicity
Clostridium Infections / diagnosis
Clostridium Infections / drug therapy*
Clostridium Infections / microbiology
Colitis, Ulcerative / complications*
Colitis, Ulcerative / diagnosis
Crohn Disease / complications*
Crohn Disease / diagnosis
Female
Humans
Male
Middle Aged
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Anti-Infective Agents
Antibodies, Monoclonal
Antibodies, Neutralizing
Broadly Neutralizing Antibodies
bezlotoxumab

Associated data

ClinicalTrials.gov/NCT01241552
ClinicalTrials.gov/NCT01513239